Nemolizumab,
does it really help with Itch response and skin-nodule clearance in moderate-to-severe prurigo nodularis?
research showsNemolizumab substantially improves severe itch and skin nodules in prurigo nodularis but is rated C. OLYMPIA 1 randomized and analyzed 286 participants by intention to treat. At week 16, a four-point or greater itch response occurred in 58.4% versus 16.7% (difference 40.1 percentage points, P<0.001), and Investigator's Global Assessment success occurred in 26.3% versus 7.3% (P=0.003), so both coprimary outcomes succeeded. OLYMPIA 2 replicated the outcomes in 274 randomized and analyzed participants, at 56.3% versus 20.9% and 37.7% versus 11.0%. Both trials, however, belonged to the same Galderma development program and do not provide independent replication.
ads claimLarge week-16 response rates should not be translated into complete clearance for every patient or permanent remission after treatment stops. Investigator's Global Assessment success occurred in only 26.3% of treated participants in OLYMPIA 1.
Useful facts when choosing a product
- Nemolizumab is a monoclonal antibody targeting interleukin-31 receptor alpha and is given by subcutaneous injection.
- OLYMPIA 1 used weight-based dosing every four weeks: 30 mg below 90 kg and 60 mg at or above 90 kg.
- A four-point Peak Pruritus Numerical Rating Scale response is a clinical symptom-response threshold, not a laboratory surrogate.
What the research actually shows
In OLYMPIA 1, both coprimary outcomes succeeded among 286 intention-to-treat participants: four-point itch response was 58.4% versus 16.7% (P<0.001), and Investigator's Global Assessment success was 26.3% versus 7.3% (P=0.003). OLYMPIA 2 replicated both among 274 participants at 56.3% versus 20.9% (P<0.0001) and 37.7% versus 11.0% (P<0.0001). The OLYMPIA reports prespecified the four-point itch reduction as clinically meaningful. Both trials exceeded 200 participants, lasted 16 weeks, and were double-blind, but they belonged to the same Galderma program.
Why this is classified as C (55)
Both patient-centered itch response and clinical nodule assessment coprimary outcomes succeeded with large effects in two phase 3 trials. With no independently funded confirmation outside the Galderma program, the verdict is C with 55 points.
Counterpoint. Itch is a direct treatment target and the absolute difference in clinically meaningful response was large. The true efficacy signal and the independence limitation should be read together.
Rejudgment record. Cross-check applied — Success of both itch and skin-nodule coprimary outcomes in both phase 3 trials, with a ceiling because all evidence comes from one manufacturer development program
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Itch response of at least four points | C | The coprimary outcome succeeded with large absolute differences in both phase 3 trials. |
| Investigator's Global Assessment success for skin nodules | C | This coprimary outcome succeeded in both phase 3 trials. |
| Improved itch-related sleep disturbance | C | Key secondary outcomes in the OLYMPIA program showed substantial improvement. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ständer S et al. 2025 (OLYMPIA 1) | Multicenter randomized double-blind placebo-controlled phase 3 trial | 286 | Galderma; the sponsor participated in design, conduct, analysis, manuscript preparation, and submission | Coprimary week-16 four-point Peak Pruritus Numerical Rating Scale response and Investigator's Global Assessment success | Both coprimary outcomes succeeded: 58.4% versus 16.7% (P<0.001) and 26.3% versus 7.3% (P=0.003). | Pivotal manufacturer phase 3 trial |
| Kwatra SG et al. 2023 (OLYMPIA 2) | Multicenter randomized double-blind placebo-controlled phase 3 trial | 274 | Galderma; the same manufacturer development program as OLYMPIA 1 | Coprimary week-16 four-point itch response and Investigator's Global Assessment success | Both coprimary outcomes succeeded: 56.3% versus 20.9% (P<0.0001) and 37.7% versus 11.0% (P<0.0001). | Replication within the same manufacturer program |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Nemolizumab x itch and skin-nodule improvement in prurigo nodularis — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/nemolizumab-prurigo-nodularis-itch-nodule-clearance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.